THURSDAY, Dec. 19, 2024 (HealthDay News) — The U.S. Food and Drug Administration re-issued a decision first made by the agency in October that a shortage of the diabetes/weight-loss medication tirzepatide is over. Tirzepatide includes blockbuster injected GLP-1 medications Mounjaro (for diabetes) and Zepbound (for weight loss). The FDA firstContinue Reading

THURSDAY, Dec. 12, 2024 (HealthDay News) — Unhealthy ultra-processed foods have wormed their way into American kitchens, likely harming people’s health for decades, a new study warns. More than half of the calories adults eat at home now come from ultra-processed foods, which contain high levels of sugar, salt, fatContinue Reading

WEDNESDAY, Dec. 4, 2024 (HealthDay News) — Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly. “Given the increased interest around obesity medications, we conducted this study to help health care providers and patients makeContinue Reading